Phoenix Energy Announces Notice of Effectiveness of Registration Statement on Form S-1
Irvine, California, May 20, 2025 (GLOBE NEWSWIRE) -- Phoenix Energy One, LLC ('Phoenix Energy' or the 'Company'), an energy company specializing in oil production, mineral rights acquisitions, and non-operating working interests, recently announced that the Securities and Exchange Commission (the 'SEC') has declared the Company's registration statement on Form S-1 (File No. 333-282862) effective.
The registration statement, including the related prospectus, relates to the issuance of up to an aggregate principal amount of $750 million of debt securities that the Company intends to offer on a continuous basis pursuant to Rule 415 of the Securities Act of 1933, as amended. As further described in the prospectus, the Company is offering notes with maturities of three, five, seven, or eleven years and with interest rates of 9%, 10%, 11%, or 12% per annum, respectively. The interest is payable either in cash or by adding such interest to the then-outstanding principal amount of the notes.
As a result of the effectiveness of the registration statement, the Company became subject to the reporting obligations of the Securities Exchange Act of 1934, as amended, requiring it to, among other things, file Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K with the SEC.
The notes are offered through Dalmore Group, LLC ('Dalmore'), a member of FINRA/ SIPC. Dalmore and Phoenix Energy are not affiliated.
The offering may be made only by means of a prospectus. Before investing, any investor should read the prospectus and the other documents Phoenix Energy has filed with the SEC, which may be obtained for free by visiting EDGAR on the SEC's website at www.sec.gov. Alternatively, a copy of the applicable offering documents may be obtained directly from Phoenix Energy or Dalmore. This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities, and shall not constitute an offer, solicitation, or sale of any security, in any jurisdiction in which such offering, solicitation, or sale would be unlawful. Any offers, solicitations, or offers to buy, or any sales of, these securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.
About Phoenix Energy
Founded in 2019 and headquartered in Irvine, California, Phoenix Energy is an innovative energy company specializing in oil production, mineral rights royalty acquisition, and non-operating working interests. Phoenix Energy's drilling operations are focused on the Williston Basin (North Dakota and Montana), as well as the Powder River and DJ Basins (Wyoming). Its royalty and working interest acquisitions target mineral, leasehold, overriding, and perpetual royalty interests across major U.S. basins, prioritizing asset quality over location.
CONTACTS:
Company: Phoenix Energy One, LLCEmail: InvestorRelations@phoenixenergy.comAddress: 18575 Jamboree Road, Suite 830, Irvine, CA 92612Phone: 949-416-5037
Company: Dalmore GroupEmail phoenix@dalmoregroup.comAddress: 530 7th Avenue, Suite 902, New York, NY 10018Phone: 332-239-2407
Attachment
Phoenix Energy Announces Notice of Effectiveness of Registration Statement on Form S-1
CONTACT: Mark Kaley Phoenix Energy 407-394-5881 mark.kaley@otterpr.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
4 hours ago
- The Hill
Novo Nordisk, GoodRx selling Ozempic at half cost for customers paying cash
Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to patients who pay for the medications with cash. Starting this week, customers will be able to buy a month's supply of Novo Nordisk's semaglutide pen products for $499 through GoodRx. The list price for a monthly supply of a product like Ozempic is normally around $1,000 or more without insurance. 'Demand for GLP-1 medications is at an all-time high, but too many Americans still face barriers accessing them,' GoodRx CEO and President Wendy Barnes said in a statement. 'By partnering with Novo Nordisk, we're taking a significant step forward in making these innovative brand-name treatments more accessible for millions of people who need them,' added Barnes. 'It's a powerful example of how the GoodRx platform can deliver savings at scale—bridging gaps in coverage and ensuring more people can get the care they deserve.' This is the most recent in similar moves Novo Nordisk has made to make its popular diabetes and weight loss medication more widely available. Earlier this year, the company announced a direct-to-patient program called NovoCare® Pharmacy for uninsured and underinsured individuals who can pay $499 a month for Wegovy. Novo Nordisk also partnered with online telehealth companies like Ro and LifeMD to sell its pens at the same price point. The telehealth company Hims & Hers was also originally included in the partnership, but Novo Nordisk ended it after accusing the company of illegally selling compounded versions of semaglutide. Hims & Hers maintains it is providing personalized, compounded products within regulatory guidelines. 'Improving access to effective FDA-approved treatment is central to our mission, and our collaboration with GoodRx allows us to reach those who seek savings and support from their trusted and established platform,' Dave Moore, executive vice president of U.S. operations of Novo Nordisk, said in a statement. 'This initiative enables us to meet GoodRx patients where they are with our authentic GLP-1 medicines in addition to supporting the launch of the new Ozempic® self-pay offer for type 2 diabetes patients at an unprecedented price.' Sen. Bernie Sanders (I-Vt.), a prominent critic of high drug costs, called the announcement a 'modest step forward.' 'Novo Nordisk's move to cut the price of Ozempic to $499 for the uninsured is a modest step forward, but let's not forget,' Sanders said on the social media platform X. 'Ozempic costs just $59 in Germany while it costs less than $5 to make. The U.S. must no longer pay the highest prices in the world for prescription drugs.
Business Wire
4 hours ago
- Business Wire
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
NEW YORK--(BUSINESS WIRE)--TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ('TNF' or the 'Company'), a clinical stage biopharmaceutical company committed to developing novel therapies for autoimmune and inflammatory conditions, today announced that is has significantly improved its financial position over the past 5 months through a material reduction in liabilities, while maintaining total assets of over $17 million as of June 30, 2025. 'The recent significant improvement in our financial position gives TNF a stronger platform for growth opportunities and taking advantage of shareholder value creation opportunities,' said TNF President and Chief Medical Officer, Mitchell Glass, M.D. 'We are pleased to have the continued support of our largest investors, and look forward to updating investors on TNF's business developments in the near future, including our ongoing collaboration with Renova on GLP-induced inflammation and muscle damage.' The improvements in the Company's financial position will be reflected in future financial statements of the Company. About TNF Pharmaceuticals, Inc. TNF Pharmaceuticals, Inc. (Nasdaq: TNFA), a clinical stage pharmaceutical company committed to extending healthy lifespan, is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical stage small molecule that regulates the immune system to control TNF-α, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. The Company's second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the rapidly growing CBD market, which includes both FDA approved drugs and CBD products not currently regulated as drugs. For more information, visit Cautionary Statement Regarding Forward-Looking Statements This press release may contain forward-looking statements. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to be materially different from any expected future results, performance, or achievements. Forward-looking statements speak only as of the date they are made and neither the Company nor its affiliates assume any duty to update forward-looking statements. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'may,' 'plan,' 'will,' 'would'' and other similar expressions are intended to identify these forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, without limitation: unanticipated financial setbacks, the Company needing to pursue financing options that could adversely impact our liabilities due to adverse market conditions, the Company's ability to maintain compliance with the Nasdaq Stock Market's listing standards; the timing of, and the Company's ability to, obtain and maintain regulatory approvals for clinical trials of the Company's pharmaceutical candidates; the timing and results of the Company's planned clinical trials for its pharmaceutical candidates; the amount of funds the Company requires for its pharmaceutical candidates; increased levels of competition; changes in political, economic or regulatory conditions generally and in the markets in which the Company operates; the Company's ability to retain and attract senior management and other key employees; the Company's ability to quickly and effectively respond to new technological developments; and the Company's ability to protect its trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on the Company's proprietary rights. A discussion of these and other factors with respect to the Company is set forth in the Company's Annual Report on Form 10-K for the year ended December 31, 2024, filed by the Company on April 11, 2025, and subsequent reports that the Company files with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and the Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Business Wire
4 hours ago
- Business Wire
Lucky Strike Entertainment Declares Common Stock Dividend
RICHMOND, Va.--(BUSINESS WIRE)--Lucky Strike Entertainment (NYSE: LUCK), one of the world's premier owner/operators of location-based entertainment, today declared a regular quarterly cash dividend of $0.055 per common share. The dividend is payable on September 12, 2025, to stockholders of record on August 29, 2025. About Lucky Strike Entertainment Lucky Strike Entertainment is one of the world's premier location-based entertainment platforms. With over 360 locations across North America, Lucky Strike Entertainment provides experiential offerings in bowling, amusements, water parks, and family entertainment centers. The company also owns the Professional Bowlers Association, the major league of bowling and a growing media property that boasts millions of fans around the globe. For more information on Lucky Strike Entertainment, please visit Forward Looking Statements Some of the statements contained in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risk, assumptions and uncertainties, such as statements of our plans, objectives, expectations, intentions and forecasts. These forward-looking statements are generally identified by the use of forward-looking terminology, including the terms "anticipate," "believe," 'confident,' 'continue,' "could," "estimate," "expect," "intend," 'likely,' "may," "plan," 'possible,' "potential," "predict," "project," "should," "target," "will," "would" and, in each case, their negative or other various or comparable terminology. These forward-looking statements reflect our views with respect to future events as of the date of this release and are based on our management's current expectations, estimates, forecasts, projections, assumptions, beliefs and information. Although management believes that the expectations reflected in these forward-looking statements are reasonable, it can give no assurance that these expectations will prove to have been correct. All such forward-looking statements are subject to risks and uncertainties, many of which are outside of our control, and could cause future events or results to be materially different from those stated or implied in this document. It is not possible to predict or identify all such risks. These risks include, but are not limited to: our ability to design and execute our business strategy; changes in consumer preferences and buying patterns; our ability to compete in our markets; the occurrence of unfavorable publicity; risks associated with long-term non-cancellable leases for our locations; our ability to retain key managers; risks associated with our substantial indebtedness and limitations on future sources of liquidity; our ability to carry out our expansion plans; our ability to successfully defend litigation brought against us; our ability to adequately obtain, maintain, protect and enforce our intellectual property and proprietary rights and claims of intellectual property and proprietary right infringement, misappropriation or other violation by competitors and third parties; failure to hire and retain qualified employees and personnel; the cost and availability of commodities and other products we need to operate our business; cybersecurity breaches, cyber-attacks and other interruptions to our and our third-party service providers' technological and physical infrastructures; catastrophic events, including war, terrorism and other conflicts; public health emergencies and pandemics, such as the COVID-19 pandemic, or natural catastrophes and accidents; changes in the regulatory atmosphere and related private sector initiatives; fluctuations in our operating results; economic conditions, including the impact of increasing interest rates, inflation and recession; and other factors described under the section titled 'Risk Factors' in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the 'SEC') by the Company on September 5, 2024, as well as other filings that the Company will make, or has made, with the SEC, such as Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in other filings. We expressly disclaim any obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law.
